Extrait

The primary objective of this study is to estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) CSCC (Group 1) or with unresectable locally advanced CSCC (Group 2), as measured by ORR, according to central review.

Critère d'inclusion

• Advanced Cutaneous Squamous Cell Carcinoma